Search Results
Your search for Matthew Stenger matches 162 pages
Showing 51 - 100Addition of Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery in Advanced Ovarian Cancer
In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by van Driel et al, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery following neoadjuvant chemotherapy was associated with significantly improved recurrence-free and...
Addition of Pazopanib to Paclitaxel in Persistent or Recurrent Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Richardson et al found that the addition of pazopanib to paclitaxel did not improve progression-free survival among women with persistent or recurrent ovarian cancer. Study Details In the double-blind study, 106 women from 26 U.S. study sites with...
Predictors of Cervical Precancer Treatment Failure
In a meta-analysis reported in The Lancet Oncology, Arbyn et al found that posttreatment high-risk human papillomavirus (HPV) testing was a better predictor of recurrence of high-grade cervical intraepithelial neoplasia of grade 2 or higher (CIN2+) than incomplete cervical excision. Study Details ...
Immunotherapy in PD-L1–Positive Advanced Cervical Cancer
Pembrolizumab (Keytruda) treatment was active in patients with programmed cell death ligand 1 (PD-L1)–positive advanced cervical cancer enrolled in the phase Ib KEYNOTE-028 trial. The findings were reported by Frenel et al in the Journal of Clinical Oncology. Study Details In the advanced...
Novel Adverse Genomic Rearrangement Signature in High-Grade Serous Ovarian Cancer
As reported by Hillman et al in the Journal of the National Cancer Institute, a novel genomic rearrangement signature associated with poorer overall survival has been identified in high-grade serous ovarian cancer. Study Details In the study, clinical data and whole-genome sequencing results were ...
CD8-Positive Tumor-Infiltrating Lymphocytes and Survival in High-Grade Serous Ovarian Cancer
As reported in JAMA Oncology by Goode et al in the Ovarian Tumor Tissue Analysis Consortium, higher levels of cytotoxic CD8-positive tumor-infiltrating lymphocytes were associated with significantly improved overall survival among women with high-grade serous ovarian carcinomas. Study Details The ...
Final Efficacy Analysis of 9-Valent Human Papillomavirus Vaccine Trial
The final efficacy analysis of a trial of 9-valent human papillomavirus (HPV) vaccine has shown a high preventive effect against disease due to the additional HPV pathogenic strains covered compared with the quadrivalent vaccine at up to 6 years. These findings were reported by Huh et al in The...
Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer
As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...
Olaparib Tablets as Maintenance in BRCA1/2-Mutant Platinum-Sensitive Relapsed Ovarian Cancer
A phase III trial (SOLO2/ENGOT-Ov21) has shown improved progression-free survival with an olaparib tablet formulation vs placebo as maintenance therapy in patients with BRCA1/2-mutant platinum-sensitive relapsed ovarian cancer. These study results were reported by Pujade-Lauraine et al in The...
Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis
A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...
Tumor Microvessel Density and Outcome With Bevacizumab in Ovarian Cancer
A retrospective biomarker analysis of the phase III GOG-0218 trial indicated a higher tumor microvessel density was associated with progression-free and overall survival benefit with bevacizumab (Avastin) vs placebo plus front-line chemotherapy in patients with ovarian cancer. These findings were...
Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer
Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...
Durvalumab With Olaparib or Cediranib in Women’s Cancers
As reported in the Journal of Clinical Oncology by Lee et al, a phase I study has shown activity of the combination of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab with either the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) or vascular endothelial growth...
Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer
In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...
Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy for Stage I Endometrial Cancer
A multinational equivalence trial has shown no difference in disease-free survival with total laparoscopic hysterectomy vs total abdominal hysterectomy in women with treatment-naive stage I endometrial cancer. The findings were reported by Janda et al in JAMA. Study Details In the trial, 760...
Evidence of Stage Shift in Ovarian Cancer Detected in UK Screening Study
As reported in the Journal of Clinical Oncology, Rosenthal et al found evidence of a shift to an earlier stage among ovarian cancers detected in high-risk women in the UK Familial Ovarian Cancer Screening Study. Study Details The study was performed to evaluate performance of screening using...
Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum
In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...
Comparison of Sentinel Lymph Node Biopsy vs Lymphadenectomy in Endometrial Cancer Staging
In the FIRES prospective cohort study reported in The Lancet Oncology, Rossi et al found that sentinel lymph node mapping was highly accurate in detecting metastases compared with complete lymphadenectomy in women with endometrial cancer. Study Details The study included women with clinical stage ...
Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?
Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a phase I expansion cohort study reported in the Journal of...
Diagnostic Laparoscopy May Predict Result of Primary Cytoreductive Surgery in Suspected Advanced Ovarian Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Rutten et al found that initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery in patients with suspected advanced-stage ovarian cancer. Study Details In the trial, 201 women who were qualified for primary...
Rucaparib Appears Effective in Relapsed Platinum-Sensitive High-Grade Ovarian Carcinoma
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Swisher et al found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapsed platinum-sensitive high-grade ovarian carcinoma who had...
No Advantage to Adding Seribantumab to Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer, but Subgroup May Benefit
In a phase II study reported in the Journal of Clinical Oncology, Liu et al found no progression-free survival benefit of adding the anti-HER3 (ErbB3) antibody seribantumab to paclitaxel in unselected patients with advanced platinum-resistant or -refractory ovarian cancer. However, exploratory...
Study Finds Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial reported at the recent European Society for Medical Oncology Congress and in The New England Journal of Medicine by Mirza et al, maintenance therapy with the PARP (poly ADP ribose polymerase) 1/2 inhibitor niraparib significantly prolonged progression-free survival vs placebo...
Survival Benefit Reported With Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al....
Study Suggests Role of Bilateral Oophorectomy in Preventing Premenopausal Breast Cancer in BRCA2- but Not BRCA1-Mutation Carriers
Bilateral oophorectomy was associated with prevention of premenopausal breast cancer in BRCA2- but not BRCA1-mutation carriers, according to a study reported by Kotsopoulos et al in the Journal of the National Cancer Institute. The study included 3,722 women with BRCA mutations in a prospective...
Shorter Survival Reported With Neoadjuvant Chemotherapy vs Primary Reductive Surgery in Stage IIIC Ovarian Cancer
Neoadjuvant chemotherapy was associated with shorter survival vs primary cytoreductive surgery in patients with stage IIIC ovarian cancer, according to a multi-institute observational study reported by Meyer et al in the Journal of Clinical Oncology. The study involved 1,538 women with stage IIIC...
Study Finds HIV Infection Linked to Reduced Survival Among Women With Cervical Cancer in Botswana
Despite access to and use of antiretroviral therapy, HIV (human immunodeficiency virus) infection was associated with reduced survival in women with cervical cancer in Botswana, according to a study reported by Dryden-Peterson et al in the Journal of Clinical Oncology. Study Details The study...
Predicted Burden of Cervical Cancer With vs Without Effective Screening in Baltic, Central, and Eastern European Countries
Vaccarella et al estimated changes in the incidence of cervical cancer through 2040 in six Baltic, central, and eastern European (BCEE) countries on the hypotheses of continued absence of effective screening programs vs progressive implementation of such programs. Their findings were reported in...
ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer
As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...
Recommendations for Surveillance of Premature Ovarian Insufficiency in Female Survivors of CAYA Cancers
Harmonized recommendations for surveillance of premature ovarian insufficiency in female survivors of childhood, adolescent, and young adult (CAYA) cancers have been published by van Dorp et al in the Journal of Clinical Oncology on behalf of the International Late Effects of Childhood Cancer...
Potential Increased Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation
In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer...
No Overall Advantage to Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer, but Subgroup May Benefit
According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Kurzeder et al found that adding pertuzumab (Perjeta) to investigator’s choice of chemotherapy did not improve progression-free survival in women with low-HER3 mRNA–expressing...
Study Finds Apparent Benefit of Adding Fosbretabulin to Bevacizumab in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma
Adding the vascular-disrupting agent fosbretabulin to bevacizumab (Avastin) improved outcomes in patients with recurrent ovarian, tubal, or peritoneal carcinoma, according to a randomized phase II NRG Oncology/Gynecologic Oncology Group study reported in the Journal of Clinical Oncology by Monk et...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Bailey et al, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States. In the United States, HPV is estimated to cause approximately 99.7% of cervical cancers, 60% of...
Study Reports No Overall Benefit of Adding Farletuzumab to Chemotherapy in Relapsed Ovarian Cancer, but Potential Subgroup Benefit Identified
Addition of the antifolate receptor-α antibody farletuzumab to carboplatin/taxane did not improve progression-free survival in patients with ovarian cancer in first platinum-sensitive relapse, reported Vergote et al in the Journal of Clinical Oncology. However, benefit was observed in...
Adding Cediranib to Platinum Therapy Increases Progression-Free Survival in Relapsed Platinum-Sensitive Ovarian Cancer
The phase III ICON6 trial showed that adding cediranib to platinum-based therapy increased progression-free survival and toxicity in women with first relapse of platinum-sensitive ovarian cancer, reported Ledermann et al in The Lancet. Study Details In the double-blind trial, 456 women with...
Fosaprepitant Combination Reduces Risk of Emesis During Chemoradiotherapy for Cervical Cancer
The addition of fosaprepitant (Emend) to palonosetron and dexamethasone reduced the risk of emesis during 5 weeks of chemoradiotherapy for cervical cancer, according to the phase III GAND-emesis trial reported in The Lancet Oncology by Ruhlmann et al. Study Details In the double-blind trial, 234...
Frequent Copy Number Gain of Genes for PD-1 Ligands in Squamous Cell Carcinoma of the Cervix or Vulva
In a study reported in JAMA Oncology, Howitt et al identified copy number gain of genes encoding programmed cell death protein 1 (PD-1) ligands in a sizable proportion of patients with squamous cell carcinoma of the cervix or vulva. Study Details The study involved fluorescence in situ...
Study Finds No Progression-Free Survival Benefit for Weekly Dose-Dense vs Every-3-Week Paclitaxel Plus Carboplatin in Ovarian Cancer
Weekly dose-dense paclitaxel did not provide a progression-free survival benefit over every-3-week paclitaxel in combination with carboplatin and with or without elective bevacizumab (Avastin) in patients with previously untreated ovarian cancer, according to the results of the phase III GOG-0262...
Study Finds No Adverse Impact of Minimally Invasive Hysterectomy on Long-Term Survival in Endometrial Cancer
Use of minimally invasive hysterectomy did not seem to have an adverse impact on long-term survival in women with endometrial cancer, according to an analysis reported in the Journal of Clinical Oncology by Wright et al. Study Details The study involved Surveillance, Epidemiology, and End Result...
UK Study Suggests Potential Mortality Benefit of Ovarian Cancer Screening in Postmenopausal Women
As reported in The Lancet by Jacobs et al, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) suggests there may be a mortality benefit of ovarian cancer screening in postmenopausal women. Study Details In the trial, 202,546 postmenopausal women aged 50 to 74 years from 13 centers...
Study Shows ACA Coverage Expansion Resulted in Increased Cervical Cancer Diagnosis at Early Stage in Young Women
In a study reported in a research letter in JAMA, Robbins et al found evidence that the Affordable Care Act Dependent Coverage Expansion (ACA-DCE) has resulted in increased diagnosis of cervical cancer at an early stage and increased use of fertility-sparing treatments in women aged 21 to 25 years. ...
European Trial Shows Front-Line Addition of Nintedanib to Standard Chemotherapy Improves Progression-Free Survival in Advanced Ovarian Cancer
In a European phase III trial (AGO-OVAR 12) reported in The Lancet Oncology, du Bois et al found that adding the antiangiogenic multikinase inhibitor nintedanib (Ofev) to carboplatin/paclitaxel improved progression-free survival in patients with newly diagnosed ovarian cancer. Gastrointestinal...
Addition of Cediranib to Carboplatin/Paclitaxel Improves Progression-Free Survival in Metastatic/Recurrent Cervical Cancer in UK Phase II Trial
In a UK phase II trial reported in The Lancet Oncology, Symonds et al found that the addition of the investigational VEGFR1, -2, and -3 inhibitor cediranib to carboplatin/paclitaxel improved progression-free survival in patients with metastatic or relapsed cervical cancer. The addition of cediranib ...
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer
Results of the phase III AHT trial reported in the Journal of Clinical Oncology by Eeles et al suggest that adjuvant hormonal therapy may improve survival in women with epithelial ovarian cancer. The trial, started in 1990, was stopped early due to low recruitment. Study Details In the open-label ...
Therapeutic HPV-16/18 Vaccine Produces Regression of Cervical Intraepithelial Neoplasia Grade 2/3 in Phase II Trial
In a phase IIb trial reported in The Lancet, Trimble et al found that a therapeutic synthetic vaccine (VGX-3100) targeting human papillomavirus (HPV) 16 and 18 E6 and E7 proteins increased the frequency of regression of HPV-16/18–related cervical intraepithelial neoplasia grade 2/3 vs...
Co-infection With High-Risk and Low-Risk HPV Reduces Risk of Squamous Cervical Cancer vs High-Risk HPV Alone
In a study reported in the Journal of the National Cancer Institute, Sundström et al found that women co-infected with high-risk and low-risk human papillomavirus (HPV) had reduced risk of squamous cervical cancer (SCC), but not cancer in situ (CIS) compared with women with high-risk HPV...
Study Explores Link Between MAPK Pathway Alteration and Long-Term Response to MEK Inhibitor in Serous Ovarian Cancer
In a study reported in the Journal of Clinical Oncology, Grisham et al identified a novel alteration in the MAP2K1 gene encoding for MEK1 that appeared to explain a complete response ongoing for more than 5 years in a patient treated with the MEK inhibitor selumetinib for metastatic low-grade...
Japanese Phase II Trial Shows Activity of Nivolumab in Platinum-Resistant Ovarian Cancer
In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hamanishi et al found that the anti–PD-1 (programmed cell death protein 1) antibody nivolumab (Opdivo) was active in patients with relapsed or advanced platinum-resistant ovarian cancer. Study Details In the study,...
Analysis Indicates That Tubal Ligation Is Associated With Lower Endometrial Cancer Stage at Diagnosis and Improved Survival
In an analysis from the NRG Oncology/Gynecologic Oncology Group 210 trial reported in the Journal of the National Cancer Institute, Felix et al found that tubal ligation, which should impede transtubal passage of cells, was associated with lower stage of endometrial cancer at presentation and...
